Eyestem - About the company
Eyestem is a series B company based in Bengaluru (India), founded in 2015 by Rajani Ravindra Battu, Dhruv Sareen, Rajarshi Pal and Jogin B Desai. It operates as a Developer of scalable cell replacement therapies. Eyestem has raised $20M in funding from investors like Alkem Laboratories, Biological E and C-CAMP, with a current valuation of ₹*****. The company has 187 active competitors, including 75 funded and 29 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.
Company Details
Developer of scalable cell replacement therapies. The company focuses on creating a cell therapy platform to treat incurable diseases and democratize access to medical technologies. Its lead product is aimed at treating age-related macular degeneration. The organization utilizes embedded manufacturing and quality processes to support innovation and facilitate the development of therapeutic solutions.
- Website
- eyestem.com
- Social
- Email ID
- *****@eyestem.com
- Registered Address
- Centre for Cellular and Molecular Platforms, GKVK Campus, Bellary Road, Bangalore, Bangalore, Karnataka, India, 560065
Key Metrics
Founded Year
2015
Location
Bengaluru, India
Stage
Series B
Total Funding
$20M in 7 rounds
Latest Funding Round
Post Money Valuation
₹***** as on Oct 08, 2025
Investors
Ranked
28th among 187 active competitors
Annual Revenue
0 - ₹10 Cr as on Mar 31, 2025
Employee Count
23 as on May 31, 2026
Similar Companies
Legal entities associated with Eyestem
Eyestem is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
EYESTEM RESEARCH PRIVATE LIMITED CIN: U74999KA2015PTC164505 , India, Active | Aug 25, 2015 | 0 - ₹10 Cr (As on Mar 31, 2025) | 23 (As on May 31, 2026) |
Sign up to download Eyestem's company profile
Eyestem's funding and investors
Eyestem has raised a total funding of $20M over 7 rounds. Its first funding round was on Oct 28, 2016. Its latest funding round was a Series B round on Jul 15, 2025 for $*****. 10 investors participated in its latest round. Eyestem has 22 institutional investors and 11 angel investors.
Here is the list of recent funding rounds of Eyestem:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 15, 2025 | 3953007 | Series B | 7006840 | 6764823 | 1562417 | 1892005 |
Aug 08, 2022 | 2669185 | Series A | 7739748 | 1317296 | 4020571 | |
May 24, 2021 | 5672194 | Seed | 4036405 | 5492965 | 9725497 |
Access funding benchmarks and valuations. Sign up today!View details of Eyestem's funding rounds and investors
Eyestem's founders and board of directors
Founder? Claim ProfileThe founders of Eyestem are Rajani Ravindra Battu, Dhruv Sareen, Rajarshi Pal and Jogin B Desai. Jogin B Desai is the CEO of Eyestem.
Here are the details of Eyestem's key team members:
- Rajani Ravindra Battu: Co-Founder & CMO of Eyestem. They serve on the board of 1 company.Contact Info: 1 email address and 1 phone number
- Dhruv Sareen: Co-Founder of Eyestem. They serve on the board of 1 company.Contact Info: 1 phone number
- Rajarshi Pal: Co-Founder of Eyestem. Contact Info: 1 email address and 1 phone number
- Jogin B Desai: Co-Founder & CEO of Eyestem.
Eyestem's Board of Directors
Eyestem's board has 9 active members. Ramesh Babu Byrapaneni, Sandeep Singh, Shirish Rajendra Barwale, Rajani Ravindra Battu, Dhruv Sareen, Ashok N Vohra and Ramaswamy Subramanian are part of team and Gerardus Adrianus Hoogland and Ferzaan Nariman Engineer are independent board members.Here is the list of Eyestem's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 11y 0m | |
Team | - | Current | 10y 1m | |
vtymtgo | Team | - | Current | 4y 1m |
fyqetwu | Team | - | Current | 2y 2m |
Investor | - | Current | 2y 3m | |
Investor | - | Current | 1y 0m | |
hmcdkku | Investor | tczfush | Current | 9y 3m |
Independent board member | - | Current | 0y 5m | |
igmxgzb | Independent board member | - | Past | 3y 5m |
View details of Eyestem's Founder profiles and Board Members
Eyestem's employee count trend
Eyestem has 23 employees as of May 26. The total employee count is 44.0% more than what it was in May 25. Here is Eyestem's employee count trend over the years:
Uncover Eyestem's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Eyestem's Competitors and alternates
Top competitors of Eyestem include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Eyestem, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | 4D Molecular Therapeutics 2013, Emeryville (United States), Public | Developer of gene therapeutics for genetic disorders | $187M | 67/100 | |
2nd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
3rd | Developer of mRNA-based therapeutics against cancer and infectious diseases | $975M | 67/100 | ||
4th | Kala Pharmaceuticals 2009, Waltham (United States), Public | Developer of ophthalmic treatments based on its mucosal penetrating product platform | $115M | 66/100 | |
5th | Aspen Neuroscience 2018, San Diego (United States), Series C | Provider of genomic-based personalised pluripotent stem cell therapy | $339M | 65/100 | |
6th | Rezolute 2012, Denver (United States), Public | Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | - | 64/100 | |
7th |  AAVantgarde Bio 2021, Milano (Italy), Series B | Developer of gene therapies using Adeno-Associated Viral vectors | $206M | 63/100 | |
8th | Blue Rock Therapeutics 2016, Boston (United States), Acquired | Stem cell therapies for cardiovascular and neurological diseases | $225M | 62/100 | |
9th | Aviceda Therapeutics 2018, Cambridge (United States), Series C | Developer of biotherapeutics for glycol-immune diseases | $255M | 62/100 | |
10th | Epicrispr Bio 2018, San Francisco (United States), Series C | Developer of therapeutics for multiple disease | $245M | 62/100 | |
28th | Developer of scalable cell replacement therapies | $20M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Eyestem's competitors? Click here to see the top ones
Eyestem's Latest cap tables and shareholding
Founders own 22.86%, Funds own 15.72%, Enterprises (largest shareholder) own 47.33% and Angels own 6.70%. The net worth of Eyestem's founders is INR 135Cr as of Oct 08, 2025.
Shareholders Name | Post Round Holding % | Net worth | Cumulative Investment | Realised Returns | Unrealised Returns | Return Multiple |
|---|---|---|---|---|---|---|
Founder | 22.86% | 135Cr | 6581100 | 5301617 | 6790971 | 3431108 |
657 | 693 | 726 | 565 | 711 | 285 | |
5 | 5 | 5 | 1 | 4 | 5 | |
0 | 0 | 0 | 0 | 0 | 0 | |
Fund | 15.72% | 93.1Cr | 2536633 | 9052409 | 3985581 | 5572484 |
3618954 | 9128139 | 4402808 | 9290585 | 3405620 | 3057010 | |
3 | 8 | 3 | 5 | 2 | 6 | |
Enterprise | 47.33% | 280Cr | 8511210 | 7165434 | 1359422 | 6378320 |
Angel | 6.70% | 39.7Cr | 624543 | 659355 | 852362 | 953247 |
23 | 55 | 87 | 32 | 80 | 30 | |
Other People | 0.89% | 5.28Cr | 0 | 0 | 0 | 0 |
ESOP Pool | 6.49% | 38.4Cr | 437442 | 187528 | 715422 | 682067 |
Total | 100.00% | 592Cr | 4556194 | 1707066 | 8045447 | 7834284 |
To unlock detailed Cap Table of Eyestem Sign up today!Notes: The column Net Worth represents the net worth of investments made by that entity, as per the latest cap table.
DisclaimerView more details of Eyestem's Shareholding
Eyestem's Investments and acquisitions
Eyestem has made no investments or acquisitions yet.
Reports related to Eyestem
Here is the latest report on Eyestem's sector:
News related to Eyestem
Filter this listMedia has covered Eyestem for a total of 2 events in the last 1 year.
•
•
•
India’s pharma and healthcare funding declines in August 2025Express Pharma•Sep 03, 2025•Aragen, Eyestem, Aethermt, QRL Bioscience and 2 others
•
Eyestem Research Secures USD 10 Million in Series B FundingEnablers•Aug 11, 2025•Eyestem, Mahyco, Alkem Laboratories
•
Eyestem Announces Completion of Phase 1 Study of its RPE Cell TherapyBioSpectrum India•Jun 18, 2025•Eyestem
•
•
Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patients
Indiatimes•Apr 14, 2025•Eyestem
•
Eyestem’s pioneering Dry AMD treatment receives positive recommendation from Drug Safety Monitoring Board (DSMB)BioSpectrum India•Oct 24, 2024•Eyestem
•
Eyestem completes first set of patient injections for Dry AMD treatmentIndiatimes•Sep 09, 2024•Eyestem
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Eyestem
Explore our recently published companies
- Carvarisa - Unfunded company
- Moerke and Sons Pump and Drilling - Chehalis based, 1980 founded, Unfunded company
- Nicolas Abramowicz - Phoenix based, Unfunded company
- Starboard Strategy - Cincinnati based, Unfunded company
- Rocky Mountain Dock and Door Specialties - Littleton based, Unfunded company
- Friend Associates - Unfunded company
